Enhancement of rAAV2 Viral Vector Yield Recovery in Upstream Lysate Material

Pharmaron’s innovative adeno-associated virus (AAV) high-throughput process platform approach provides rapid access to increased titres and higher recoveries. AAV serotypes differ in their propensity to be secreted from the host cell, often requiring a lysis step to release AAV serotypes otherwise retained within the cytoplasm.

To learn more about the enhancement of rAAV2 Viral Vector Yield Recovery, please complete the form below to download the poster: Enhancement of rAAV2 Viral Vector Yield Recovery in Upstream Lysate Material.